| Popis: |
To investigate outcomes including efficacy, quality of life, and levels of inflammatory markers of a mandibular advancement device (MAD) for moderate-to-severe obstructive sleep apnea (OSA).Case-control study.Patients with apnea-hypopnea index (AHI) ≥ 15/hr who only accepted MAD therapy (study group) or who refused any treatment (control group) were recruited. At baseline and at 6 months, polysomnography, Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), C-reactive protein (CRP), interleukin 1β, interleukin 6, and tumor necrosis factor α (TNF-α) were assessed in both groups.At baseline, the study group (n = 30) showed a higher percentage of rapid eye movement sleep and higher CRP levels (P .05) than the control group (n = 10). At 6 months, the MAD significantly improved AHI and lowest oxygen saturation (P .01), non-rapid eye movement (N)1 and N3 sleep stages (P .05), ESS score (P .05), FOSQ total score (P .01), interleukin 1β (P .05), and TNF-α (P .01) compared with the untreated group. In the overall, moderate, and severe OSA groups, 63.3%, 75%, and 50%, respectively, achieved at least good response.Use of a MAD significantly improved polysomnographic parameters, quality of life, and some inflammatory markers (CRP, IL-β, and TNF-α) in a significant proportion of patients with moderate OSA and in some patients with severe OSA. Hence, a MAD may be a viable alternative therapy in patients with moderate-to-severe OSA who refuse continuous positive airway pressure.3b. Laryngoscope, 128:1720-1726, 2018. |
Plný text